Celldex Therapeutics, Inc. (CLDX) Stock Price & Analysis
Celldex Therapeutics, Inc. (CLDX) closed at USD 29.66 on Wednesday, October 28, 2026, down 1.63% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 30.15; the Oct 28, 2026 session ranged USD 28.92–30.02 on volume of 897,209 shares. Market capitalization is $2.33B, with a 52-week range of USD 22.1–45.14 (NCM). Source: Nexqual, retrieved October 28, 2026 at 20:35 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CLDX.md
Key facts (CLDX)
- Last four reported quarters (through Jun 30, 2026): revenue $158K, net income -$301M (-190220.9% margin), free cash flow -$242M (SEC filings).
- Analysts: Buy (mean 1.93 on a 1–5 scale) (15 analysts), mean target USD 63.07 (range 28–100).
- Total return with dividends: 1Y +14.1% vs S&P 500 +13.6%; 5Y -30.3% vs S&P 500 +79.8%.
- Next earnings: 2026-11-09, EPS estimate USD -1.01, revenue estimate $883K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CLDX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $4.7M | $2.4M | $6.9M | $7.0M | $1.5M | $158K |
| Gross profit | $4.6M | $2.3M | $6.6M | $6.8M | $1.3M | — |
| Operating income | -$71.2M | -$115M | -$155M | -$195M | -$287M | -$326M |
| Net income | -$70.5M | -$112M | -$141M | -$158M | -$259M | -$301M |
| EPS (diluted) | -$1.64 | -$2.40 | -$2.92 | -$2.45 | -$3.90 | — |
| Free cash flow | -$62.2M | -$106M | -$109M | -$160M | -$214M | -$242M |
| Gross margin | 97.8% | 95.8% | 95.6% | 97.2% | 87.1% | — |
| Operating margin | -1531.8% | -4889.0% | -2245.3% | -2778.9% | -18599.8% | -206220.3% |
| Net margin | -1516.0% | -4765.6% | -2054.8% | -2248.8% | -16748.0% | -190220.9% |
| Revenue growth | -37.3% | -49.3% | +192.0% | +2.0% | -78.0% | — |
| Cash + short-term investments | $408M | $305M | $424M | $725M | $519M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CLDX)
P/S 14741.7x · P/B 3.3x · FCF yield -10.39% · Earnings yield -12.90%
Analysts (CLDX)
Consensus Buy (mean 1.93 on a 1–5 scale), 15 analysts; mean target USD 63.07 (low 28, high 100).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-02 | HC Wainwright & Co. | Reiterated | Buy | $64 |
| 2026-09-23 | Leerink Partners | Target raised | Outperform | $70 → $88 |
| 2026-09-23 | Morgan Stanley | Target raised | Overweight | $50 → $57 |
| 2026-09-22 | HC Wainwright & Co. | Target raised | Buy | $42 → $64 |
| 2026-09-22 | Cantor Fitzgerald | Target raised | Overweight | $61 → $72 |
| 2026-09-10 | Morgan Stanley | Target raised | Overweight | $46 → $50 |
| 2026-08-07 | Morgan Stanley | Target raised | Overweight | $40 → $46 |
| 2026-08-07 | Barclays | Target raised | Overweight | $48 → $53 |
| 2026-07-29 | Wells Fargo | Target raised | Overweight | $48 → $72 |
| 2026-07-22 | Wells Fargo | Target lowered | Overweight | $54 → $48 |
| 2026-07-22 | Morgan Stanley | Target lowered | Overweight | $44 → $40 |
| 2026-07-22 | Cantor Fitzgerald | Target lowered | Overweight | $67 → $61 |
Total return (dividends reinvested) (CLDX)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +14.1% | -30.3% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +14.2% | -7.0% |
| Volatility (annualized) | 51.6% | 58.9% |
| Max drawdown | -38.6% (Aug 2026→Oct 2026) | -69.6% (Feb 2024→Mar 2025) |
CLDX earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 6, 2026 | Quarter ended Jun 30, 2026 | −$0.94 | −$1.06 | Beat +11.3% | +1.6% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$1.18 | −$1.13 | Miss −4.4% | -1.2% |
| Feb 25, 2026 | Quarter ended Dec 31, 2025 | −$1.22 | −$1.00 | Miss −22.0% | +23.3% |
| Nov 10, 2025 | Quarter ended Sep 30, 2025 | −$1.01 | −$0.89 | Miss −13.5% | +6.4% |
| Aug 7, 2025 | — | — | — | — | -3.6% |
| May 8, 2025 | — | — | — | — | -3.1% |
| Feb 27, 2025 | — | — | — | — | -0.3% |
| Nov 6, 2024 | — | — | — | — | +4.1% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
CLDX recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 7, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 10.7% of shares, passive 5%+ holder (amended) |
| Sep 22, 2026 | 8-K | Other material event “On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorporated by reference herein.” |
| Aug 14, 2026 | Schedule 13G/A | Kynam Capital Management, LP, Kynam Capital Management GP, LLC: 6.8% of shares, passive 5%+ holder (amended) |
| Aug 14, 2026 | Schedule 13G | T. Rowe Price Associates, Inc.: 6.0% of shares, passive 5%+ holder |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
| Jul 15, 2026 | 8-K | Director or executive officer change, or pay arrangement “On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the "Company"), notified the Company of his plans to retire effective on or about March 31, 2027. Mr. Martin joined the Company in April 2009 and has served as Chief Financial Officer since July 2017. The Company has initiated a search for a new Chief Financial Officer. To ensure a smooth transition of his responsibilities, Mr. Martin intends to continue to serve the Company as Chief Financial Officer…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
CLDX revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Grant | $15,000 | 68.2% | -97.9% |
| Service | $7,000 | 31.8% | +0.0% |
| Total revenue | $22,000 | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CLDX customer concentration
In the period ended Dec 31, 2025, a single direct customer accounted for 93% of revenue, per the company's 10-K filed Feb 25, 2026. The company does not name it.
CLDX company outlook (results filed Aug 6, 2026)
- “Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at June 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028.”
Quoted word-for-word from the SEC 8-K results press release.
CLDX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-1.01 | $-1.08 | +$0.07 | $883,220 | 10 |
| Next quarter (ends Dec 2026) | $-1.01 | $-1.10 | +$0.09 | $1.4M | 10 |
| Current fiscal year (ends Dec 2026) | $-4.12 | $-4.39 | +$0.27 | $1.8M | 10 |
| Next fiscal year (ends Dec 2027) | $-4.25 | $-4.50 | +$0.25 | $8.8M | 10 |
CLDX options: expected move
Options price a move of about ±13.9% (±$4.20) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±5.5% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 23 | 68.3% | ±13.9% |
| Dec 18, 2026 | 51 | 60.8% | ±18.2% |
| Jan 15, 2027 | 79 | 52.8% | ±19.7% |
| Feb 19, 2027 | 114 | 55.2% | ±24.5% |
| Mar 19, 2027 | 142 | 58.3% | ±28.8% |
| May 21, 2027 | 205 | 57.4% | ±33.7% |
30-day implied volatility 62.1% vs 58.7% realized over the last 30 trading days. Put/call ratio (volume) 1.85. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 28, 2026 at 20:35 UTC)
| Price | USD 29.66 |
|---|---|
| Change | ▼ 1.63% (down) |
| Previous Close | USD 30.15 |
| Open | USD 29.63 |
| Day Range | USD 28.92 – 30.02 |
| 52-Week Range | USD 22.1 – 45.14 |
| Volume | 897,209 shares |
| Market Cap | $2.33B |
| Exchange | NCM |
Technical Analysis (CLDX)
Nexqual's technical model rates CLDX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 28, 2026 at 20:35 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.52 (neutral) |
| vs SMA50 | Below (USD 34.49) |
| MACD | -1.31 (negative) |
Analyst Ratings (CLDX)
Wall Street analysts rate CLDX "Buy" based on 15 analysts, with a mean price target of USD 63.07 (range USD 28–100), per Nexqual as of October 28, 2026 at 20:35 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 63.07 |
| High Target | USD 100 |
| Low Target | USD 28 |
| Buy / Hold / Sell | 14 / 1 / 0 |
Earnings (CLDX)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -1.01 |
| Revenue Estimate | $883,220 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.94 vs est -1.06 ▲ beat |
| 2026-03-31 | USD -1.18 vs est -1.13 ▼ miss |
| 2025-12-31 | USD -1.22 vs est -1 ▼ miss |
| 2025-09-30 | USD -1.01 vs est -0.89 ▼ miss |
Source: Nexqual, October 28, 2026 at 20:35 UTC.
Financials & Fundamentals (CLDX)
| Total Revenue | $158,000 |
|---|---|
| Revenue Growth (latest quarter, YoY) | -97.00% |
| Gross Margin | +0.00% |
| Operating Margin | -366468.20% |
| Profit Margin | +0.00% |
| ROE | -43.88% |
| Debt / Equity | 0.01 |
| Current Ratio | 11.82 |
| Total Cash | $717.59M |
| Total Debt | $4.90M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$242.10M (-153231.0% of revenue) |
Source: Nexqual, October 28, 2026 at 20:35 UTC.
Financial Health Score (CLDX)
Nexqual rates Celldex Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 28, 2026 at 20:35 UTC.
| Growth | Critical — Revenue -78% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $718M cash vs $5M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$242M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -42%, ROA -38.4% (last 4 quarters, SEC) |
Ownership (CLDX)
| Insider Ownership | +0.27% |
|---|---|
| Institutional Ownership | +109.89% |
| Shares Outstanding | 78.53M |
| Float | 73.02M |
| Short % of Float | +14.51% |
Source: Nexqual, October 28, 2026 at 20:35 UTC.
Leadership (CLDX)
Celldex Therapeutics, Inc. is led by Anthony S. Marucci, Founder, President, CEO & Director, per Nexqual as of October 28, 2026 at 20:35 UTC.
| Founder, President, CEO & Director | Anthony S. Marucci |
|---|---|
| Founder, Chief Scientific Officer & Executive VP | Tibor Keler |
| Senior VP, CFO, Secretary & Treasurer | Sam Martin |
| Chief Product Development Officer & Senior VP | Elizabeth Crowley |
| Senior Vice President of Regulatory Affairs | Margo Heath-Chiozzi |
Major Backers & Investors (CLDX)
Notable institutional backers of Celldex Therapeutics, Inc. include Wellington Management, Kynam Capital Management, LP, Price (T.Rowe) Associates Inc, according to Nexqual as of October 28, 2026 at 20:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 12.15% |
| Kynam Capital Management, LP | 6.78% |
| Price (T.Rowe) Associates Inc | 5.97% |
| FMR, LLC | 4.74% |
| Deep Track Capital, Lp | 3.74% |
| T. Rowe Price | 2.84% |
| Logos Global Management LP | 2.67% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.92% |
| State Street | 4.97% |
| Vanguard Group | 4.41% |
Source: Nexqual, October 28, 2026 at 20:35 UTC.
From Celldex Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- We are the owner or exclusive licensee to proprietary patent positions in the areas of immunotherapy technologies and antibody technologies.
- In the United States, the FDA regulates drugs and biological products under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Service Act, or PHSA, and implementing regulations.
- In general, our intellectual property strategy is to protect our technology by filing patent applications and obtaining patent rights covering our own technology, both in the United States and in foreign countries that we consider important to our business.
Partnerships
- Under a license agreement with Yale, we may be required to make a one-time payment to Yale of $3.0 million with respect to barzolvolimab upon achievement of a specified commercial milestone.
Legal & Regulatory Risks (Item 1A, quoted)
- The results of preclinical studies and early clinical trials may not be predictive of the results of later- stage clinical trials, and interim results of a clinical trial do not necessarily predict final results.
- We may have delays in commencing, enrolling and completing our clinical trials, and we may not complete them at all.
- We may expend our resources to pursue a particular drug candidate or indication and forgo the opportunity to capitalize on drug candidates or indications that may ultimately be more profitable or for which there is a greater likelihood of success.
- Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 20:35 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt